These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 47888)

  • 21. Complement receptor binding of C3b-coated cells treated with C3b inactivator, beta 1H globulin and trypsin.
    Carlo JR; Ruddy S; Studer EJ; Conrad DH
    J Immunol; 1979 Aug; 123(2):523-8. PubMed ID: 88474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human complement component C4. Structural studies on the fragments derived from C4b by cleavage with C3b inactivator.
    Press EM; Gagnon J
    Biochem J; 1981 Nov; 199(2):351-7. PubMed ID: 6978710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.
    Harpel PC; Cooper NR
    J Clin Invest; 1975 Mar; 55(3):593-604. PubMed ID: 123251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The binding site of human C4b-binding protein on complement C4 is localized in the alpha'-chain.
    Hessing M; van 'T Veer C; Bouma BN
    J Immunol; 1990 Apr; 144(7):2632-7. PubMed ID: 2319131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A single arginine to tryptophan interchange at beta-chain residue 458 of human complement component C4 accounts for the defect in classical pathway C5 convertase activity of allotype C4A6. Implications for the location of a C5 binding site in C4.
    Ebanks RO; Jaikaran AS; Carroll MC; Anderson MJ; Campbell RD; Isenman DE
    J Immunol; 1992 May; 148(9):2803-11. PubMed ID: 1573269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of functional recombinant von Willebrand factor-A domain from human complement C2: a potential binding site for C4 and CRIT.
    Hui KM; Orriss GL; Schirmer T; Magnadóttir B; Schifferli JA; Inal JM
    Biochem J; 2005 Aug; 389(Pt 3):863-8. PubMed ID: 15823096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.
    Ziegler JB; Alper CA; Rosen RS; Lachmann PJ; Sherington L
    J Clin Invest; 1975 Mar; 55(3):668-72. PubMed ID: 1117072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of different forms of human C4b-binding protein lacking beta-chain and protein S binding ability.
    Hessing M; Kanters D; Hackeng TM; Bouma BN
    Thromb Haemost; 1990 Oct; 64(2):245-50. PubMed ID: 2148654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The third component of complement and complement receptors (author's transl)].
    Okuda T; Tachibana T
    Tanpakushitsu Kakusan Koso; 1974 Sep; 19(9):657-67. PubMed ID: 4215099
    [No Abstract]   [Full Text] [Related]  

  • 32. Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator.
    Fujita T; Gigli I; Nussenzweig V
    J Exp Med; 1978 Oct; 148(4):1044-51. PubMed ID: 702059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of complement receptor type 1-related proteins on primate erythrocytes.
    Nickells MW; Subramanian VB; Clemenza L; Atkinson JP
    J Immunol; 1995 Mar; 154(6):2829-37. PubMed ID: 7876553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection.
    Alper CA; Abramson N; Johnston RB; Jandl JH; Rosen FS
    J Clin Invest; 1970 Nov; 49(11):1975-85. PubMed ID: 4097977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reactive haemolysis--a distinctive form of red cell lysis.
    Thompson RA; Rowe DS
    Immunology; 1968 May; 14(5):745-62. PubMed ID: 4172980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion.
    Tas SW; Klickstein LB; Barbashov SF; Nicholson-Weller A
    J Immunol; 1999 Nov; 163(9):5056-63. PubMed ID: 10528211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of functional properties of C4-binding protein by monoclonal antibodies.
    Fujita T; Kamato T; Tamura N
    J Immunol; 1985 May; 134(5):3320-4. PubMed ID: 3872332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Action of the C3b-inactivator on the cell-bound C3b.
    Law SK; Fearon DT; Levine RP
    J Immunol; 1979 Mar; 122(3):759-65. PubMed ID: 448074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antigen-bound C3b and C4b enhance antigen-presenting cell function in activation of human T-cell clones.
    Arvieux J; Yssel H; Colomb MG
    Immunology; 1988 Oct; 65(2):229-35. PubMed ID: 2973431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.